vs
Apellis Pharmaceuticals, Inc.（APLS）与Five9, Inc.（FIVN）财务数据对比。点击上方公司名可切换其他公司
Five9, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$300.3M vs $199.9M），Five9, Inc.同比增速更快（7.8% vs -5.9%），Five9, Inc.自由现金流更多（$77.3M vs $-14.3M），过去两年Five9, Inc.的营收复合增速更高（10.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Five9是全球领先的云原生联络中心软件及解决方案供应商，服务零售、医疗、金融服务、科技等行业的各规模企业，提供全渠道客户互动、AI驱动自动化、劳动力管理、数据分析等工具，助力企业提升客户体验与运营效率。
APLS vs FIVN — 直观对比
营收规模更大
FIVN
是对方的1.5倍
$199.9M
营收增速更快
FIVN
高出13.7%
-5.9%
自由现金流更多
FIVN
多$91.6M
$-14.3M
两年增速更快
FIVN
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $300.3M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 55.4% |
| 营业利润率 | -25.6% | 6.6% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 7.8% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFIVN
| Q4 25 | $199.9M | $300.3M | ||
| Q3 25 | $458.6M | $285.8M | ||
| Q2 25 | $178.5M | $283.3M | ||
| Q1 25 | $166.8M | $279.7M | ||
| Q4 24 | $212.5M | $278.7M | ||
| Q3 24 | $196.8M | $264.2M | ||
| Q2 24 | $199.7M | $252.1M | ||
| Q1 24 | $172.3M | $247.0M |
净利润APLSFIVN
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $18.0M | ||
| Q2 25 | $-42.2M | $1.2M | ||
| Q1 25 | $-92.2M | $576.0K | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-4.5M | ||
| Q2 24 | $-37.7M | $-12.8M | ||
| Q1 24 | $-66.4M | $-7.1M |
毛利率APLSFIVN
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 55.0% | ||
| Q2 25 | — | 54.9% | ||
| Q1 25 | — | 55.0% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | 53.0% | ||
| Q1 24 | — | 53.6% |
营业利润率APLSFIVN
| Q4 25 | -25.6% | 6.6% | ||
| Q3 25 | 48.7% | 5.6% | ||
| Q2 25 | -18.6% | -0.6% | ||
| Q1 25 | -50.0% | -1.9% | ||
| Q4 24 | -12.3% | 1.5% | ||
| Q3 24 | -24.0% | -5.8% | ||
| Q2 24 | -14.7% | -7.7% | ||
| Q1 24 | -36.0% | -8.4% |
净利率APLSFIVN
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 6.3% | ||
| Q2 25 | -23.6% | 0.4% | ||
| Q1 25 | -55.3% | 0.2% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -1.7% | ||
| Q2 24 | -18.9% | -5.1% | ||
| Q1 24 | -38.5% | -2.9% |
每股收益（稀释后）APLSFIVN
| Q4 25 | $-0.40 | $0.22 | ||
| Q3 25 | $1.67 | $0.21 | ||
| Q2 25 | $-0.33 | $0.01 | ||
| Q1 25 | $-0.74 | $0.01 | ||
| Q4 24 | $-0.30 | $0.16 | ||
| Q3 24 | $-0.46 | $-0.06 | ||
| Q2 24 | $-0.30 | $-0.17 | ||
| Q1 24 | $-0.54 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $232.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $785.8M |
| 总资产 | $1.1B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFIVN
| Q4 25 | $466.2M | $232.1M | ||
| Q3 25 | $479.2M | $193.4M | ||
| Q2 25 | $370.0M | $205.5M | ||
| Q1 25 | $358.4M | $370.3M | ||
| Q4 24 | $411.3M | $362.5M | ||
| Q3 24 | $396.9M | $291.0M | ||
| Q2 24 | $360.1M | $175.7M | ||
| Q1 24 | $325.9M | $240.2M |
总债务APLSFIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSFIVN
| Q4 25 | $370.1M | $785.8M | ||
| Q3 25 | $401.2M | $775.3M | ||
| Q2 25 | $156.3M | $717.4M | ||
| Q1 25 | $164.2M | $664.3M | ||
| Q4 24 | $228.5M | $622.2M | ||
| Q3 24 | $237.1M | $565.6M | ||
| Q2 24 | $264.3M | $525.9M | ||
| Q1 24 | $266.7M | $483.6M |
总资产APLSFIVN
| Q4 25 | $1.1B | $1.8B | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $821.4M | $1.7B | ||
| Q1 25 | $807.3M | $2.1B | ||
| Q4 24 | $885.1M | $2.1B | ||
| Q3 24 | $901.9M | $2.0B | ||
| Q2 24 | $904.5M | $1.9B | ||
| Q1 24 | $831.9M | $1.9B |
负债/权益比APLSFIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $83.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $77.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 25.8% |
| 资本支出强度资本支出/营收 | 0.1% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $201.2M |
8季度趋势，按日历期对齐
经营现金流APLSFIVN
| Q4 25 | $-14.2M | $83.6M | ||
| Q3 25 | $108.5M | $59.2M | ||
| Q2 25 | $4.4M | $35.1M | ||
| Q1 25 | $-53.4M | $48.4M | ||
| Q4 24 | $19.4M | $49.8M | ||
| Q3 24 | $34.1M | $41.1M | ||
| Q2 24 | $-8.3M | $19.9M | ||
| Q1 24 | $-133.0M | $32.4M |
自由现金流APLSFIVN
| Q4 25 | $-14.3M | $77.3M | ||
| Q3 25 | $108.3M | $48.7M | ||
| Q2 25 | $4.4M | $31.6M | ||
| Q1 25 | $-53.4M | $43.7M | ||
| Q4 24 | $19.3M | $40.5M | ||
| Q3 24 | — | $26.7M | ||
| Q2 24 | $-8.4M | $13.1M | ||
| Q1 24 | $-133.3M | $20.4M |
自由现金流率APLSFIVN
| Q4 25 | -7.1% | 25.8% | ||
| Q3 25 | 23.6% | 17.0% | ||
| Q2 25 | 2.5% | 11.1% | ||
| Q1 25 | -32.0% | 15.6% | ||
| Q4 24 | 9.1% | 14.5% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | -4.2% | 5.2% | ||
| Q1 24 | -77.3% | 8.3% |
资本支出强度APLSFIVN
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 3.3% | ||
| Q3 24 | 0.0% | 5.4% | ||
| Q2 24 | 0.0% | 2.7% | ||
| Q1 24 | 0.2% | 4.8% |
现金转化率APLSFIVN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.29× | ||
| Q2 25 | — | 30.38× | ||
| Q1 25 | — | 84.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FIVN
暂无分部数据
